Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?

Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, Baumann M, Troost EGC, Hölscher T.

Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30954-0. doi: 10.1016/j.eururo.2018.11.050. [Epub ahead of print]

PMID:
30578119
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.

Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de Ridder M.

Clin Transl Oncol. 2018 Apr;20(4):484-490. doi: 10.1007/s12094-017-1736-9. Epub 2017 Aug 9.

PMID:
28795303
4.

(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.

Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T.

Strahlenther Onkol. 2016 Jul;192(7):431-9. doi: 10.1007/s00066-016-0982-z. Epub 2016 Jun 7.

PMID:
27272755
5.

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N.

Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review.

PMID:
27363387
6.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
7.

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. doi: 10.1007/s00259-015-3240-1. Epub 2015 Nov 12.

PMID:
26563121
8.

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.

Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM.

Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.

PMID:
30425003
9.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
10.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

11.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
12.

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.

Udovicich C, Perera M, Hofman MS, Siva S, Del Rio A, Murphy DG, Lawrentschuk N.

Prostate Int. 2017 Dec;5(4):125-129. doi: 10.1016/j.prnil.2017.02.003. Epub 2017 Feb 24. Review.

13.

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7.

PMID:
29308527
14.

The utility of prostate-specific antigen in the management of advanced prostate cancer.

Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.

BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4. Review.

15.

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.

BJU Int. 2017 Aug;120(2):197-203. doi: 10.1111/bju.13739. Epub 2017 Jan 4.

16.

Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

Kim M, Lee J, Jeong CW, Ku JH, Kim HH, Kwak C.

Urol Oncol. 2015 May;33(5):203.e1-9. doi: 10.1016/j.urolonc.2015.01.017. Epub 2015 Feb 26.

PMID:
25726498
17.

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94. doi: 10.1007/s00259-015-3078-6. Epub 2015 May 15.

PMID:
25975367
18.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, Lesperance J, Porter C, Sterbis J, McLeod DG.

Urol Oncol. 2014 Aug;32(6):761-8. doi: 10.1016/j.urolonc.2014.03.024. Epub 2014 Jun 11.

19.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

20.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258

Supplemental Content

Support Center